MG
MAIA icon

Mather Group’s MAIA Biotechnology MAIA Stock Holding History

Mather Group’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,060
Closed -$26.5K – 1989
2024
Q2 		$26.5K Buy
12,060
+12,036
+50,150% +$37.9K ﹤0.01% 1197
2024
Q1 		$28 Buy
+24
New +$36 ﹤0.01% 1741

Other funds holding MAIA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Mather Group's MAIA Position: Q3 2024 in Review

Mather Group sold out of MAIA Biotechnology (MAIA) in Q3 2024, closing a stake of 12,060 shares — an estimated $26.5K sold.

Mather Group first reported a position in MAIA in Q1 2024 and held it in 2 quarters. The position peaked at $26.5K in Q2 2024. 17 funds tracked by Wall St. Rank hold MAIA as of Q3 2024.

  • Mather Group reported no remaining MAIA Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Mather Group sold 12,060 MAIA Biotechnology shares in Q3 2024, an estimated $26.5K.
  • Mather Group first reported a position in MAIA Biotechnology in Q1 2024 and held it in 2 quarters.
  • Mather Group's MAIA Biotechnology position peaked at $26.5K in Q2 2024.
  • 17 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.